Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 23-Oct-23 1:06 PM View:  | Altchem Ltd 10% Owner | Rvl Pharmaceuticals Plc (RVLP) | 20-Oct-23 | Sale | 4,758,900 | $0.03 | $148,478.00 | (44%) 10.88M to 6.12M | |
| 23-Oct-23 4:23 PM View: | Harsaul Foundation 10% Owner | Rvl Pharmaceuticals Plc (RVLP) | 20-Oct-23 | Sale Duplicate | 4,758,900 | $0.03 | $148,478.00 | (49%) 9.7M to 4.94M | |
| 23-Oct-23 1:06 PM View: | Altchem Ltd 10% Owner | Rvl Pharmaceuticals Plc (RVLP) | 19-Oct-23 | Sale | 9,363,760 | $0.05 | $431,669.00 | (46%) 20.25M to 10.88M | |
| 23-Oct-23 4:23 PM View: | Harsaul Foundation 10% Owner | Rvl Pharmaceuticals Plc (RVLP) | 19-Oct-23 | Sale Duplicate | 9,363,760 | $0.05 | $431,669.00 | (49%) 19.06M to 9.7M | |
| 20-Oct-23 3:59 PM View: | Harsaul Foundation 10% Owner | Rvl Pharmaceuticals Plc (RVLP) | 18-Oct-23 | Sale Duplicate | 3,421,540 | $0.06 | $221,031.00 | (15%) 22.49M to 19.06M | |
| 20-Oct-23 1:36 PM View: | Altchem Ltd 10% Owner | Rvl Pharmaceuticals Plc (RVLP) | 18-Oct-23 | Sale | 3,421,540 | $0.06 | $221,031.00 | (14%) 23.67M to 20.25M | |
| 17-Aug-23 5:04 PM View: | Avista Healthcare Partners ... 10% Owner | Rvl Pharmaceuticals Plc (RVLP) | 15-Aug-23 | Disposition (other) | 23,730,900 | -- | -- | (100%) 23.73M to 0 | |
| 14-Aug-23 5:35 PM View: | Lask Alisa Director | Rvl Pharmaceuticals Plc (RVLP) | 10-Aug-23 | Payment of Exercise | 12,000 | $0.49 | $5,880.00 | (10%) 124.56K to 112.56K | |
| 11-Jul-23 9:17 PM View: | Debiasi Michael J. Director | Rvl Pharmaceuticals Plc (RVLP) | 05-Jul-23 | Grant | 40,000 | -- | -- | 100% 0 to 40.0K | |
| 11-Jul-23 9:16 PM View: | Cowan Gregory L Director | Rvl Pharmaceuticals Plc (RVLP) | 05-Jul-23 | Grant | 40,000 | -- | -- | 80% 50.05K to 90.06K | |
| 11-Jul-23 9:15 PM View: | Lask Alisa Director | Rvl Pharmaceuticals Plc (RVLP) | 05-Jul-23 | Grant | 40,000 | -- | -- | 47% 84.56K to 124.56K | |
| 22-May-23 9:18 PM View: | Klein Christopher General Counsel & Secretary | Rvl Pharmaceuticals Plc (RVLP) | 18-May-23 | Payment of Exercise | 5,447 | $0.87 | $4,738.89 | (3%) 186.02K to 180.57K | |
| 22-May-23 9:21 PM View: | Schaub James EVP and COO | Rvl Pharmaceuticals Plc (RVLP) | 18-May-23 | Payment of Exercise | 5,577 | $0.87 | $4,851.99 | (1%) 530.41K to 524.84K | |
| 30-Jan-23 5:29 PM View: | Burgstahler David F Director 10% Owner | Rvl Pharmaceuticals Plc (RVLP) | 27-Jan-23 | Disposition (other) Duplicate | 1,033,000 | -- | -- | (4%) 24.76M to 23.73M | |
| 30-Jan-23 5:28 PM View: | Venkataraman Sriram Director 10% Owner | Rvl Pharmaceuticals Plc (RVLP) | 27-Jan-23 | Disposition (other) Duplicate | 1,033,000 | -- | -- | (4%) 24.76M to 23.73M | |
| 30-Jan-23 5:27 PM View: | Avista Capital Partners III... 10% Owner | Rvl Pharmaceuticals Plc (RVLP) | 27-Jan-23 | Disposition (other) | 1,033,000 | -- | -- | (4%) 24.76M to 23.73M | |
| 26-Jan-23 5:15 PM View: | Schaub James EVP and COO | Rvl Pharmaceuticals Plc (RVLP) | 24-Jan-23 | Payment of Exercise | 9,608 | $1.26 | $12,106.10 | (2%) 540.02K to 530.41K | 9% |
| 26-Jan-23 5:16 PM View: | Klein Christopher General Counsel & Secretary | Rvl Pharmaceuticals Plc (RVLP) | 24-Jan-23 | Payment of Exercise | 9,608 | $1.26 | $12,106.10 | (5%) 195.63K to 186.02K | 9% |
| 12-Aug-22 4:07 PM View: | Lask Alisa Director | Rvl Pharmaceuticals Plc (RVLP) | 10-Aug-22 | Grant | 75,000 | -- | -- | 785% 9.56K to 84.56K | |
| 09-Aug-22 5:23 PM View: | Schaub James EVP and COO | Rvl Pharmaceuticals Plc (RVLP) | 08-Aug-22 | Purchase | 150,000 | $1.55 | $232,500.00 | 38% 390.02K to 540.02K | |
| 09-Aug-22 5:18 PM View: | Avista Healthcare Partners,... 10% Owner | Rvl Pharmaceuticals Plc (RVLP) | 08-Aug-22 | Purchase | 8,000,000 | $1.55 | $12,400,000.00 | 48% 16.76M to 24.76M | |
| 09-Aug-22 5:19 PM View: | Venkataraman Sriram Director 10% Owner | Rvl Pharmaceuticals Plc (RVLP) | 08-Aug-22 | Purchase Duplicate | 8,000,000 | $1.55 | $12,400,000.00 | 48% 16.76M to 24.76M | |
| 09-Aug-22 5:22 PM View: | Markison Brian A Chief Executive Officer Director | Rvl Pharmaceuticals Plc (RVLP) | 08-Aug-22 | Purchase | 850,000 | $1.55 | $1,317,500.00 | 40% 2.13M to 2.98M | |
| 09-Aug-22 5:21 PM View: | Burgstahler David F Director 10% Owner | Rvl Pharmaceuticals Plc (RVLP) | 08-Aug-22 | Purchase Duplicate | 8,000,000 | $1.55 | $12,400,000.00 | 48% 16.76M to 24.76M | |
| 20-May-22 4:27 PM View: | Klein Christopher General Counsel & Secretary | Rvl Pharmaceuticals Plc (RVLP) | 18-May-22 | Payment of Exercise | 6,127 | $1.40 | $8,577.80 | (3%) 201.75K to 195.63K | |
| 20-May-22 4:28 PM View: | Devries Tina Marie EVP, Research & Development | Rvl Pharmaceuticals Plc (RVLP) | 18-May-22 | Payment of Exercise | 5,447 | $1.40 | $7,625.80 | (4%) 141.59K to 136.14K | |
| 20-May-22 4:25 PM View: | Schaub James EVP and COO | Rvl Pharmaceuticals Plc (RVLP) | 18-May-22 | Payment of Exercise | 6,273 | $1.40 | $8,782.20 | (2%) 396.29K to 390.02K | |
| 26-Jan-22 4:30 PM View: | Schaub James EVP and COO | Rvl Pharmaceuticals Plc (RVLP) | 24-Jan-22 | Payment of Exercise | 9,607 | $1.13 | $10,855.90 | (2%) 405.9K to 396.29K | (2%) |
| 26-Jan-22 4:31 PM View: | Einhorn Andrew J. Chief Financial Officer | Rvl Pharmaceuticals Plc (RVLP) | 24-Jan-22 | Payment of Exercise | 9,607 | $1.13 | $10,855.90 | (6%) 173.93K to 164.32K | (2%) |
| 26-Jan-22 4:31 PM View: | Klein Christopher General Counsel & Secretary | Rvl Pharmaceuticals Plc (RVLP) | 24-Jan-22 | Payment of Exercise | 9,607 | $1.13 | $10,855.90 | (5%) 211.36K to 201.75K | (2%) |
| 26-Jan-22 4:31 PM View: | Devries Tina Marie EVP, Research & Development | Rvl Pharmaceuticals Plc (RVLP) | 24-Jan-22 | Payment of Exercise | 9,607 | $1.13 | $10,855.90 | (6%) 151.19K to 141.59K | (2%) |
| 20-Dec-21 5:03 PM View: | Schaub James EVP and COO | Rvl Pharmaceuticals Plc (RVLP) | 16-Dec-21 | Market Purchase | 93,800 | $1.07 | $100,366.00 | 30% 312.1K to 405.9K | (8%) |
| 03-Sep-21 10:00 PM View: | Weiss Fred G Director | Rvl Pharmaceuticals Plc (RVLP) | 27-Aug-21 | Payment of Exercise | 5,506 | $3.31 | $18,224.90 | (4%) 123.97K to 118.47K | (5%) |
| 07-Jul-21 4:05 PM View: | Weiss Fred G Director | Rvl Pharmaceuticals Plc (RVLP) | 02-Jul-21 | Grant | 61,188 | -- | -- | 97% 62.78K to 123.97K | |
| 22-Jun-21 4:06 PM View: | Weiss Fred G Director | Rvl Pharmaceuticals Plc (RVLP) | 18-Jun-21 | Payment of Exercise | 18,584 | $2.89 | $53,707.80 | (23%) 81.37K to 62.78K | < 1% |
| 22-Jun-21 4:05 PM View: | Cowan Gregory L Director | Rvl Pharmaceuticals Plc (RVLP) | 18-Jun-21 | Payment of Exercise | 18,584 | $2.89 | $53,707.80 | (25%) 74.14K to 55.56K | < 1% |
| 20-May-21 4:06 PM View: | Einhorn Andrew J. Chief Financial Officer | Rvl Pharmaceuticals Plc (RVLP) | 18-May-21 | Payment of Exercise | 6,467 | $3.12 | $20,177.00 | (4%) 180.4K to 173.93K | 2% |
| 20-May-21 4:06 PM View: | Klein Christopher General Counsel & Secretary | Rvl Pharmaceuticals Plc (RVLP) | 18-May-21 | Payment of Exercise | 6,467 | $3.12 | $20,177.00 | (3%) 217.83K to 211.36K | 2% |
| 20-May-21 4:05 PM View: | Devries Tina Marie EVP, Research & Development | Rvl Pharmaceuticals Plc (RVLP) | 18-May-21 | Payment of Exercise | 6,467 | $3.12 | $20,177.00 | (4%) 157.66K to 151.19K | 2% |
| 20-May-21 4:07 PM View: | Schaub James EVP and COO | Rvl Pharmaceuticals Plc (RVLP) | 18-May-21 | Payment of Exercise | 6,621 | $3.12 | $20,657.50 | (2%) 318.72K to 312.1K | 2% |
| 26-Jan-21 7:03 PM View: | Klein Christopher General Counsel & Secretary | Rvl Pharmaceuticals Plc (RVLP) | 24-Jan-21 | Payment of Exercise | 9,605 | $4.46 | $42,838.30 | (4%) 227.43K to 217.83K | (3%) |
| 26-Jan-21 7:01 PM View: | Devries Tina Marie EVP, Research & Development | Rvl Pharmaceuticals Plc (RVLP) | 24-Jan-21 | Payment of Exercise | 9,597 | $4.46 | $42,802.60 | (6%) 167.26K to 157.66K | (3%) |
| 26-Jan-21 7:03 PM View: | Schaub James EVP and COO | Rvl Pharmaceuticals Plc (RVLP) | 24-Jan-21 | Payment of Exercise | 9,687 | $4.46 | $43,204.00 | (3%) 328.41K to 318.72K | (3%) |
| 26-Jan-21 7:01 PM View: | Weiss Fred G Director | Rvl Pharmaceuticals Plc (RVLP) | 24-Jan-21 | Payment of Exercise | 5,505 | $4.46 | $24,552.30 | (6%) 86.87K to 81.37K | (3%) |
| 26-Jan-21 7:02 PM View: | Einhorn Andrew J. Chief Financial Officer | Rvl Pharmaceuticals Plc (RVLP) | 24-Jan-21 | Payment of Exercise | 9,668 | $4.46 | $43,119.30 | (5%) 190.07K to 180.4K | (3%) |
| 26-Jan-21 7:00 PM View: | Cowan Gregory L Director | Rvl Pharmaceuticals Plc (RVLP) | 24-Jan-21 | Payment of Exercise | 5,505 | $4.46 | $24,552.30 | (7%) 79.65K to 74.14K | (3%) |
| 23-Nov-20 5:10 PM View: | Avista Capital Partners III... 10% Owner | Rvl Pharmaceuticals Plc (RVLP) | 20-Nov-20 | Disposition (other) | 4,936,930 | -- | -- | (23%) 21.7M to 16.76M | |
| 23-Nov-20 5:11 PM View: | Burgstahler David F Director 10% Owner | Rvl Pharmaceuticals Plc (RVLP) | 20-Nov-20 | Disposition (other) Duplicate | 4,936,930 | -- | -- | (23%) 21.7M to 16.76M | |
| 23-Nov-20 5:13 PM View: | Venkataraman Sriram Director 10% Owner | Rvl Pharmaceuticals Plc (RVLP) | 20-Nov-20 | Disposition (other) Duplicate | 4,936,930 | -- | -- | (23%) 21.7M to 16.76M | |
| 22-May-20 4:27 PM View: | Weiss Fred G Director | Rvl Pharmaceuticals Plc (RVLP) | 21-May-20 | Payment of Exercise | 17,778 | $4.60 | $81,778.80 | (17%) 104.65K to 86.87K |
